International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)
University at Buffalo, State University of New York · Detroit Medical Center · +19 more institutions
Abstract
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the 1950s and thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage therapy for otherwise untreatable gram-negative infections. Since their reintroduction into the clinic, significant confusion remains due to the existence of several different conventions used to describe doses of the polymyxins, differences in their formulations, outdated product information, and uncertainties about susceptibility testing that has led to lack of clarity on how to optimally utilize and dose colistin and polymyxin B. We report consensus therapeutic…
Citation impact
- FWCI
- 32.59
- Percentile
- 100%
- References
- 175
Authors
18- BTBrian T. TsujiCorresponding
University at Buffalo, State University of New York
- JMJason M. Pogue
Detroit Medical Center
- APAlexandre Prehn Zavascki
Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre
- MPMical Paul
Technion – Israel Institute of Technology, Rambam Health Care Campus
- GLGeorge L. Daikos
National and Kapodistrian University of Athens
Topics & keywords
- Polymyxin
- Colistin
- Medicine
- Intensive care medicine
- Dosing
- Polymyxin B
- Antibiotics
- Pharmacy